NeuroSense Therapeutics Ltd

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025 PrimeC has already demonstrated a significant impact on slowing disease progression and increasing survival rates in people living with ALS CAMBRIDGE, Mass. , Dec. 11, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

In participants who received PrimeC from the start of the 18-month study compared to those initially on placebo before transitioning to PrimeC, disease progression was slowed by 33% (p=0.007), demonstrated in a 58% improvement in survival rates  Consistent data across subgroups underscore the potential of PrimeC to redefine the standard of care in the treatment of ALS CAMBRIDGE, Mass. , Dec. 4, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

CAMBRIDGE, Mass. , Dec. 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

CAMBRIDGE, Mass. , Nov. 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success Parallel preparations in Canada: NeuroSense plans to submit its dossier in Q2 2025, with a regulatory decision on commercialization expected by Q1 2026 CAMBRIDGE, Mass. , Oct. 28, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

Groundbreaking PARADIGM Trial Offers New Hope for ALS Treatment CAMBRIDGE, Mass. , Oct. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

Dossier submission planned for Q2 2025; regulatory decision expected by Q1 2026 Estimated potential market opportunity: peak of $100M to $150M in annual revenue Company aims to expand approval efforts to additional global markets CAMBRIDGE, Mass. , Oct. 15, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

The preparations for the regulatory submission for early commercialization in Canada follows the positive Phase 2b trial results which show PrimeC reduces ALS disease progression by 36% and improves survival rates by 43% Company plans to seek approval in additional countries CAMBRIDGE, Mass. , Oct. 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

CAMBRIDGE, Mass. , Oct. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

The Company's intellectual property now covers the combination, formulation, and method of use of PrimeC Patent protection extends through 2042, adding four additional years to PrimeC's IP umbrella CAMBRIDGE, Mass. , Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

CAMBRIDGE, Mass. , Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

CAMBRIDGE, Mass. , Aug. 30, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

CAMBRIDGE, Mass. , Aug. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

12-month data demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigation Previous results showed PrimeC slowed disease progression by 36% and improved survival rates, highlighting its potential as a transformative ALS therapy CAMBRIDGE, Mass. , Aug. 1, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. , July 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

NeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.

This cheap biotech offers investors a play on ALS if trial data continues to impress

Disease progression was slowed by 36% (p=0.009) in participants who received PrimeC for 12 months compared to those who initially received a placebo Consistent data across multiple endpoints underscore the potential of PrimeC to redefine the ALS treatment paradigm NeuroSense planning for Phase 3 clinical study in the U.S. and Europe CAMBRIDGE, Mass. , July 1, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term  CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

CAMBRIDGE, Mass. , June 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

CAMBRIDGE, Mass. , May 20, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

PhaseV's Causal Machine Learning Predicts High Probability of Success in Multiple ALS Subgroups for NeuroSense's Phase 3 Trial CAMBRIDGE, Mass. , May 14, 2024 /PRNewswire/ -- NeuroSense Therapeutics (Nasdaq: NRSN) ("NeuroSense"),  a company developing novel treatments for severe neurodegenerative diseases, today announced that it partnered with PhaseV, a pioneer in causal machine learning (ML) for clinical trial analysis and optimization, with respect to the planned Phase 3 trial of PrimeC as a treatment for amyotrophic lateral sclerosis (ALS).

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

PrimeC slowed disease progression by 43% (p=0.02) in pre-specified high-risk ALS patients Consistent data across subgroups underscore the potential of PrimeC to redefine the ALS treatment paradigm CAMBRIDGE, Mass. , May 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Announces First Quarter 2024 Business Update

CAMBRIDGE, Mass. , April 22, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

News for NeuroSense Therapeutics Ltd Stock (NRSN)